Compare CCJ & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCJ | ONC |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | Canada | Switzerland |
| Employees | N/A | 12000 |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3B | 40.6B |
| IPO Year | 1998 | 2015 |
| Metric | CCJ | ONC |
|---|---|---|
| Price | $87.94 | $361.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $123.92 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 2.6M | 313.3K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.15% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $238,387,000.00 |
| Revenue This Year | $0.12 | $723.76 |
| Revenue Next Year | $12.11 | $15.04 |
| P/E Ratio | ★ $118.32 | $1,161.19 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $77.70 | $253.95 |
| 52 Week High | $135.24 | $385.22 |
| Indicator | CCJ | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 55.65 |
| Support Level | $83.65 | $327.01 |
| Resistance Level | $123.86 | $375.97 |
| Average True Range (ATR) | 2.78 | 6.63 |
| MACD | -0.92 | 0.26 |
| Stochastic Oscillator | 1.71 | 82.61 |
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe and is one of those uranium producers. It has three reportable segments: Uranium, Fuel Services, and Westinghouse, deriving maximum revenue from the Westinghouse segment. The Uranium segment involves the exploration for, mining, milling, purchase, and sale of uranium concentrate, while the Fuel Services segment involves the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. Westinghouse Electric Company provides products and services to nuclear reactors, including outage and maintenance services, engineering support, instrumentation and controls equipment, plant modification, and components and parts.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.